Increased left ventricular posterior wall end-diastolic thickness in adolescents with delayed diagnosis of vertically acquired HIV infection. by Miller, Robert F et al.
Miller, RF; Meghji, J; Kaski, JP; Matenga, J; Ferrand, RA (2014)
Increased left ventricular posterior wall end-diastolic thickness in ado-
lescents with delayed diagnosis of vertically-acquired HIV infection.
Journal of acquired immune deficiency syndromes (1999), 66 (4). e90-
2. ISSN 1525-4135 DOI: 10.1097/QAI.0000000000000169
Downloaded from: http://researchonline.lshtm.ac.uk/1649086/
DOI: 10.1097/QAI.0000000000000169
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Increased Left
Ventricular Posterior
Wall End-Diastolic
Thickness in
Adolescents With
Delayed Diagnosis of
Vertically Acquired HIV
Infection
To the Editors:
At least a third of HIV-infected
infants have slow progressing disease
and even without HIV treatment have a
50% probability of surviving to adoles-
cence.1,2 Hence, substantial numbers of
adolescents, infected before interven-
tions to prevent mother-to-child HIV
transmission became available, are pre-
senting to clinical services with undiag-
nosed HIV in sub-Saharan Africa. A high
burden of cardiac disease was recently
described among vertically infected ado-
lescents who attended HIV outpatient
clinics in Harare, Zimbabwe. In that
study, left ventricular (LV) hypertrophy,
deﬁned as a maximal wall thickening
z-score.2 of the LV interventricular sep-
tum, the LV posterior wall (LVPW), or
both, was observed in 67% (74/110) of
the participants. Multivariate analysis
showed no association with the partici-
pant’s age, sex, stunting, wasting, body
mass index (BMI), New York Heart
Association (NYHA) functional status,
World Health Organization (WHO) HIV
stage, CD4 count, duration or type of
antiretroviral therapy (ART), and LV
hypertrophy.3
In the general population, LVPW
thickness increases with age in healthy
adults, occurs in insulin-dependent dia-
betes mellitus in the absence of overt
cardiac disease, in the morbidly obese,
persisting despite weight loss, and in
patients with chronic inﬂammatory con-
ditions, including rheumatoid arthritis
and systemic lupus erythematosus.4
In HIV-uninfected children, increased
LVPW thickness is described to exist
in association with elevated inﬂamma-
tory biomarkers5 and in myocarditis.6
Among HIV-infected children, a small
increase in LVPW thickness in early
life predisposes these children to myo-
cardial ischemia, and all-cause mortal-
ity,4,5 and in the general population
increased LV mass is an independent
predictor of cardiovascular mortality
in adults.7 Given the signiﬁcance of
increased LVPW thickness among
these groups, we speciﬁcally investi-
gated the clinical associations of LVPW
thickening among the previously
described cohort of vertically infected
adolescents.3
One hundred and ten adolescents
aged 10–19 (median 15) years were
consecutively recruited from 2 HIV out-
patient clinics in Harare. Participant
demographics and clinical features were
recorded, and transthoracic echocardi-
ography was performed as previously
described.3 Echocardiographic parame-
ters were expressed as a deviation from
the body surface area–corrected mean
using pediatric reference ranges; an
LVPW z-score .2 was regarded as
abnormal. Associations among clinical
variables (age, sex, height-for-age
z-score (stunting), weight-for-age
z-score (wasting), BMI, WHO stage,
CD4 count, NYHA functional status,
duration and type of ART, and LVPW
thickness were assessed, and variables
showing an association at signiﬁcance
level P , 0.1 were included in a multi-
variate logistic regression analysis,
where P , 0.05 was considered signif-
icant. Ethical approval was obtained
from the London School of Hygiene
and Tropical Medicine Ethics Commit-
tee, Medical Research Council of Zim-
babwe, and the Biomedical Research
and Training Institute Institutional
Review Board, Harare. The participants
gave their assent to participate, and
written informed consent in either
English or Shona was obtained from
their guardians.
The clinical characteristics of the
study participants have been described
previously.3 Brieﬂy, 78 (71%) had been
taking ART for a median of 20 [inter-
quartile range (IQR) 5–40] months,
90% of whom were on the ﬁrst-line
ART regimen [2 nucleoside reverse
transcriptase inhibitors (including stavu-
dine or zidovudine) and a nonnucleoside
reverse transcriptase inhibitor]. The
median CD4 count was 384 cells per
microliter (IQR 171–578), 87% (96/
110) had WHO stage 3 or 4 disease,
and the median BMI z-score was
−0.69 (IQR −1.81–0.11). The median
LVPW thickness z-score was +1.82
(IQR 0.69–2.63), with a z-score .2 in
48 (44%) and .3 in 17 (15%) partici-
pants. An LVPW thickness z-score .2
was associated with an ART duration of
.12 months [odds ratio (OR) 2.60, P =
0.06], BMI ,18.5 kg/m2 (OR 2.31, P =
0.04), and wasting (weight-for-age z-
score ,−2) (OR 2.00, P = 0.07). After
adjusting for age, sex, stunting (height-
for-age z-score ,−2), WHO HIV stag-
ing, CD4 count, NYHA functional sta-
tus, and ART regimen, the LVPW
thickness was associated with a longer
ART duration (adjusted OR 3.16, 95%
conﬁdence interval 1.10–9.05) and low
BMI (adjusted OR 3.46, 95% conﬁ-
dence interval 1.25–9.60).
The high prevalence of LVPW
thickening in this cohort is striking,
and contrasts with the pattern seen in
HIV-infected younger children in the
pre-ART era. The P2C2 study in the
United States followed up HIV-
infected children (median age 2.1 years)
for a median of 5 years. The LVPW was
thinned at baseline in HIV-infected
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children compared with that in HIV-
negative controls (mean z-score −0.31,
P = 0.003)8 and reached a nadir between
2 and 6 years, but it was normalized by
7 years of age. This pattern was attrib-
uted to an early myocardial insult caus-
ing LV dilatation in younger HIV-
infected children, with a delayed LV
hypertrophic response restoring LV
thickness by late childhood.9 Where
present, LVPW thickening at baseline
was associated with increased all-cause
5- and 10-year mortalities.10
The reason for the high preva-
lence of LVPW thickening in older
children with longstanding HIV, com-
pared with that in HIV-infected adults,
age-matched HIV-negative children,
and younger HIV-infected children
remains unclear, but infers chronic
myocardial damage. Prolonged expo-
sure to HIV may cause direct damage
through viral invasion of cardiac my-
ocytes,11 HIV-induced transcriptional
activation of myocyte cellular genes,
and HIV proteins, such as gp120,
which has a negative inotropic
effect.12 LVPW thickening has been
associated with inﬂammatory condi-
tions in adults and in children; this
includes rheumatoid arthritis, systemic
lupus erythematosus, and myocardi-
tis.4–6,13 Chronic untreated HIV infec-
tion also causes systemic immune
activation, and the high prevalence of
LVPW thickening in our cohort with
longstanding untreated HIV infection
may result from chronic HIV-
mediated inﬂammation.14 Most of the
larger studies investigating the relation-
ship between HIV and cardiac structure
and function have been conducted in
Western populations. Genetic and envi-
ronmental differences in the Zimbabwean
group examined here may be partly
responsible for our unexpected ﬁndings.
Pathogens such as viruses (cytomegalo-
virus, adenovirus, and Coxsackie B),
toxoplasma, and cryptococcus, which
can affect cardiac function, may be more
common in sub-Saharan Africa.
In this study, 71% of the adoles-
cents were receiving ART, and the
longer duration of treatment was asso-
ciated with LVPW thickening. Data on
the relationship between ART expo-
sure and LVPW thickness are mixed.
Among younger HIV-infected chil-
dren, ART seems to be cardioprotec-
tive, limiting LV structural and
functional impairment,15 and the use
of zidovudine by 63% (124/196) of
HIV-infected children in the P2C2
study may explain the observed lower
rates of LVPW thickening. Studies in
HIV-infected adults have shown a more
varied response to ART, but are lim-
ited by their cross-sectional nature.
Thymidine analogs, including zidovu-
dine and stavudine, have been associ-
ated with mitochondrial toxicity,
blunted myocardial hypertrophy, and
impaired cardiac function early in
life.16,17
LVPW thickening was also asso-
ciated with a reduced BMI in this
study. Studies of HIV-negative chil-
dren with protein energy malnutrition
show mixed results with both
increased and decreased LV mass
being proportionate to body sur-
face.18–20 However, there are few data
concerning the relationship between
LVPW thickness and BMI in the con-
text of HIV infection, where the mech-
anism of wasting is known to be
different, and speciﬁc micronutrient
deﬁciencies, neuroendocrine abnor-
malities, and a correlation between
HIV viral load and poor growth have
been identiﬁed.21 It is possible that
these factors limiting general growth
in HIV-infected children have a con-
current effect on the development of
cardiac tissue.
The study had several limitations
including the use of US and European
echocardiographic reference values,
use of M-mode echocardiography,
which may overestimate wall thicken-
ing compared with that of 2D imaging,
and the cross-sectional study design,
which has inherent issues of reverse
causality. Nevertheless, it is the ﬁrst
study to demonstrate a high prevalence
of increased LVPW thickness and an
association with a low BMI and dura-
tion of receipt of ART among the
growing cohort of HIV-infected ado-
lescents with vertically acquired dis-
ease. Further prospective studies are
required to investigate pathological
mechanisms, reversibility, and prog-
nostic implications of LVPW thicken-
ing and to investigate the effect of ART
exposure at different stages of child-
hood on the long-term cardiac function
in adolescence.
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CD4 T-Lymphocyte
Percentages
Corresponding to CD4
T-Lymphocyte Count
Thresholds in a New
Staging System for HIV
Infection
To the Editors:
For epidemiologic surveillance of
HIV infection in the United States, until
this year, the staging system for adults
(published in 2008) had been separate
from the classiﬁcation system for chil-
dren (published in 1994).1,2 To design a
single staging system for both adults and
children based primarily on absolute
CD4 T-lymphocyte counts, we retained
the age-speciﬁc CD4 count thresholds
used to deﬁne the boundaries between
stages 1, 2, and 3 (called “immunologic
categories” rather than “stages” in the
1994 classiﬁcation for children). Val-
ues greater than or equal to the upper
threshold indicate stage 1, values less
than the upper threshold but greater
than or equal to the lower threshold
indicate stage 2, and values less than
the lower threshold indicate stage 3
(AIDS). For children aged ,1 year,
the lower and upper CD4 count thresh-
olds are 750 and 1500 (cells/mL); for
children aged 1 to ,6 years, they are
500 and 1000; for children aged 6
to ,13 and for adults and adolescents
aged 13 or older, they are 200 and 500.
Those staging/classiﬁcation sys-
tems used both the absolute CD4 count
and the CD4 percentage of total lym-
phocytes to classify cases into stages; if
the CD4 count and the CD4 percentage
indicated different stages, the more
advanced of the 2 stages was selected.
If one of these measurements was not
available, the classiﬁcation was based
solely on the other measurement. The
lower and upper CD4 percentage
thresholds in those staging/classiﬁca-
tion systems were 15% and 25% for
all 3 age groups of children, and 14%
and 29% for adults and adolescents.1,2
In developing an updated staging sys-
tem, we reassessed the relationship
between the CD4 counts and the CD4
percentages and selected the mean CD4
percentage corresponding to each CD4
count threshold.
We analyzed pairs of CD4 counts
and CD4 percentages from 2 data
sources: (1) the National HIV Surveil-
lance System (NHSS) of the Centers for
Disease Control and Prevention (data
received by March 31, 2013) and (2) the
HIV Research Network (HIVRN), a con-
sortium of 19 facilities providing care to
HIV-infected patients. Because data
from these 2 sources may overlap to
an unknown extent, we analyzed them
separately to avoid duplicating observa-
tions in a single analysis. After testing
several models of the relationship
between CD4 counts and CD4 percen-
tages, we concluded that a linear regres-
sion model of their natural logarithmic
transformations would be best, with the
logarithm of the CD4 percentage as the
dependent variable predicted by the
logarithm of the CD4 count: log (CD4
percentage) = Intercept + Slope · log
(CD4 count). We calculated the mean
CD4 percentage predicted by each
CD4 count threshold by placing each
CD4 count threshold in the regression
equation with the estimated Intercept
and Slope (regression coefﬁcient), and
taking the antilogarithm of the result.
The results from HIVRN data
were similar to those from NHSS data
(Table 1). Rounded to the nearest whole
percentage, the lower and upper CD4
percentage thresholds derived from
NHSS data were as follows:
• For children aged ,1 year: 26% and
34%.
• For children aged 1 to ,6 years: 22%
and 30%.
• For children aged 6 to ,13 years:
14% and 24%.
• For adults and adolescents aged $13
years: 14% and 26%.
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